@peptidepanel.bsky.socialThyroid function modulates GH peptide efficacy. T3 regulates pituitary GH expression per clinical data. If TSH, free T3, or free T4 are suboptimal, peptide protocols underperform. Audit thyroid markers before starting a protocol. See the blog for the full technical…
@peptidepanel.bsky.socialMore peptide does not equate to better clinical outcomes. Biomarkers define the ceiling for efficacy; exceeding that threshold provides no additional physiological gain. Chasing higher doses past the point of saturation is not optimization. Audit your lab data.
@peptidepanel.bsky.socialBPC-157 vs. TB-500 is not a choice of preference; it is a question of biomarker data. Clinical protocols should rely on specific mechanisms, not anecdotal reports. PeptidePanel maps lab results to the appropriate peptide targets. Data-driven. See the blog for more.
@peptidepanel.bsky.socialCRP and ESR provide the inflammation roadmap. Where these markers sit dictates which peptides to prioritize. Inflammation context must precede protocol design. Every recommendation should cite the underlying mechanism. Inflammation-first, dosing second. See our blog…
@peptidepanel.bsky.socialBPC-157 protocols depend on the target tissue. Dosing is not one-size-fits-all. Clinical markers like CRP and ESR provide the necessary context for dose selection. Tailoring the protocol to the inflammatory state improves precision.
Read more on our blog…
